|
WO2020243717A1
|
|
Optimized phenylalanine hydroxylase expression
|
|
US2020155590A1
|
|
Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
|
|
WO2020097049A1
|
|
Vector system for expressing regulatory rna
|
|
EP3773622A1
|
|
Methods of manufacturing genetically-modified lymphocytes
|
|
CN111433368A
|
|
Vector with promoter and enhancer combination for treating phenylketonuria
|
|
CN110770338A
|
|
Methods and compositions for activating tumor cytotoxicity by human gamma-delta T cells
|
|
WO2018187231A2
|
|
Compositions and methods for treating phenylketonuria
|
|
US2018256624A1
|
|
Methods and compositions for the activation of gamma-delta T-cells
|
|
AU2018205388A1
|
|
HIV immunotherapy with no pre-immunization step
|
|
US2019282639A1
|
|
Viral vectors for treating parkinson's disease
|
|
US2019078096A1
|
|
Combination vectors and methods for treating cancer
|
|
EP3402483A1
|
|
Methods and compositons for the activation of gamma-delta t-cells
|
|
US2019046633A1
|
|
Method of producing cells resistant to HIV infection
|
|
CA3028982A1
|
|
Hiv pre-immunization and immunotherapy
|
|
US2019264226A1
|
|
Non-integrating viral delivery system and methods related thereto
|
|
EP3319631A1
|
|
Hiv pre-immunization and immunotherapy
|
|
EP3307894A1
|
|
Non-integrating viral delivery system and methods of use thereof
|
